Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

BACKGROUND: A small proportion of familial hypercholesterolemia (FH) patients can adequately control this condition, although achieving the recommended targets for low-density lipoprotein cholesterol (LDL-c) levels remains a challenge. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i...

Descripción completa

Detalles Bibliográficos
Autores principales: Matta, Anthony, Bongard, Vanina, Bouisset, Frédéric, Taraszkiewicz, Dorota, Rabès, Jean-Pierre, Ferrières, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112074/
https://www.ncbi.nlm.nih.gov/pubmed/33958572
http://dx.doi.org/10.12659/MSM.928784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112074/
https://www.ncbi.nlm.nih.gov/pubmed/33958572
http://dx.doi.org/10.12659/MSM.928784

Ejemplares similares